unravel

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:54 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

BREATHE! Convention Expands Event Experience with Date and Location Change to September 2023 at World Market Center Las Vegas

Source Node:
Time Stamp: April 20, 2023 7:32 AM - Modified On: April 20, 2023 - Published By:
Source Cluster:
Republished By Plato

For Immediate Release April 20, 2023 LAS VEGAS, NV - BREATHE! Convention, the premier event for emerging technology and digital transformation, has announced a date and location change for its upcoming convention. Originally scheduled for May 3-5, 2023, at the Las Vegas Convention Center, the event now takes place from September 13-15, 2023 at The Expo at World Market Center Las Vegas. This change embodies the ongoing commitment of BREATHE! to connect ever-expanding possibilities and provide additional unique and custom sponsorship opportunities and empower attendees and participants to embrace the